However, aberrant activity of multiple other transcriptional regulators, including transcriptional cyclin-dependent kinases (CDKs), MYC and BRD4, is also critical for prostate cancer growth, metastasis and therapy resistance. This evidence concerns the gene MYC and prostate carcinoma.